- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03520946
RAMucirumab in Combination Wth TAS102 vs. TAS102 Alone in Chemotherapy Refractory Metastatic Colorectal Cancer Patients (RAMTAS)
A Phase III Study of RAMucirumab in Combination With TAS102 vs. TAS102 Monotherapy in Chemotherapy Refractory Metastatic Colorectal Cancer Patients
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
This is an interventional, prospective, randomized (1:1), controlled, open label, multicenter phase IIb study in patients with advanced metastatic colorectal cancer. The scope of the trial is to evaluate overall survival of either regimen and evaluate safety and tolerability.
Patients with advanced metastatic and inoperable, colorectal cancer who have progressed on/after or did not tolerate: fluoropyrimidines, oxaliplatin, irinotecan, anti-angiogenic therapies (bevacizumab, aflibercept, regorafenib or ramucirumab) and when indicated anti-EGFR (epidermal growth factor receptor) antibodies (cetuximab or panitumumab) will be included in this trial.
Patients will be stratified by the duration of previous anti-angiogenic therapy ≥ or <12 months in total, BRAF V600E mutation status (mutation vs. wildtype), RAS mutation status (mutation vs. wildtype), and randomized 1:1 to receive either ramucirumab/TAS102 (arm A) or TAS102 (arm B). Concurrent use of other chemotherapy is not allowed.
Two interim safety analyses will be conducted when 10 and 40 patients are fully documented in arm A after receiving 2 cycles (one 4-week cycle comprises ramucirumab 8mg/kg administered at d1 and d15 and TAS102 35mg/m2 p.o. twice daily administered on d1-5 and d8-12). The analysis will be reviewed by the lead coordinating investigator (Prof. Dr. Kasper) and members of the steering committee and then by the data safety monitoring board. It is not planned to discontinue recruitment for the interim safety analyses.
Arm A (ramucirumab/TAS102) Patients randomized to arm A will receive ramucirumab 8 mg/kg iv over 60 min on d1+15, q4w and TAS102 35mg/m2 p.o. twice daily (BID) d1-5 and 8-12, q4w until progression or intolerance or completion of 6 cycles.
Arm B (TAS102) Patients randomized to arm B will receive TAS102 35mg/m2 p.o. twice daily (BID) d1-5 and 8-12, q4w until progression, intolerance or completion of 6 cycles.
In both arms, tumor assessments (CT or MRI) are performed before enrollment/randomization and then every 8 weeks (every 2nd cycle) during therapy and every 12 weeks during follow-up until progression/relapse, death or end of follow-up. A change from CT into MRI in the follow-up period is possible at any time.
During treatment, clinical visits (blood cell counts, detection of toxicity) will be performed prior to every treatment dose of ramucirumab or every two weeks in arm B or if ramucirumab was discontinued in arm A. Safety of TAS102 +/- ramucirumab will be monitored continuously by careful monitoring of all adverse events (AEs) and serious adverse events (SAEs) reported. Every 4 weeks during therapy Quality of life (QoL) will be assessed using the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30 (EORTC-QLQ-C30) and the EuroQol 5 dimensions 5-level version (EQ-5D-5L).
Study Type
Enrollment (Actual)
Phase
- Phase 3
Contacts and Locations
Study Contact
- Name: Stefan Kasper-Virchow, Prof. Dr.
- Phone Number: 3449 +49201723
- Email: stefan.kasper@uk-essen.de
Study Contact Backup
- Name: Claudia Pauligk, Dr.
- Phone Number: 3906 +49697601
- Email: ramtas@ikf-khnw.de
Study Locations
-
-
-
Amberg, Germany, 922241
- MVZ Gesundheitszentrum St. Marien GmbH
-
Bad Saarow, Germany, 15526
- Helios Klinikum Bad Saarow
-
Berlin, Germany, 10115
- Charité - Universitätsmedizin Berlin Campus Mitte
-
Berlin, Germany, 13347
- MVZ Seestrasse
-
Dortmund, Germany, 44137
- St.-Johannes-Hospital
-
Düsseldorf, Germany, 40225
- Universitätsklinikum Düsseldorf
-
Essen, Germany, 45147
- Universitätsklinikum Essen
-
Frankfurt, Germany, 60488
- Krankenhaus Nordwest GmbH
-
Hamburg, Germany, 20246
- Universitätsklinikum Hamburg-Eppendorf
-
Hamburg, Germany, 22307
- Asklepios Klinik Hamburg Barmbek
-
Hannover, Germany, 30625
- Medizinische Hochschule Hannover
-
Herne, Germany, 44625
- Marien hospital Herne
-
Karlsruhe, Germany, 76137
- Vincentius-Diakonissen-Kliniken gAG
-
Leipzig, Germany, 04103
- Universitatsklinikum Leipzig
-
Ludwigsburg, Germany, 71640
- Klinikum Ludwigsburg
-
Mannheim, Germany, 68167
- Tagestherapiezentrum am ITM Universitätsmedizin Mannheim
-
Minden, Germany, 32429
- Johannes Wesling Klinikum Minden
-
Mönchengladbach, Germany, 41063
- Kliniken Maria Hilf GmbH
-
München, Germany, 81377
- Klinikum der Universität München-Großhadern
-
Münster, Germany, 48149
- Unversitätsklinikum Münster
-
Nürnberg, Germany, 90419
- Klinikum Nürnberg
-
Ravensburg, Germany, 88212
- Studienzentrum Onkologie Ravensburg
-
Schkeuditz, Germany, 04435
- Medcenter Nordsachsen
-
Schweinfurt, Germany, 97422
- Leopoldina Krankenhaus
-
Stade, Germany, 21680
- MVZ Klinik Dr. Hancken GmbH
-
Ulm, Germany, 89081
- Universitätsklinikum Ulm
-
Wilhelmshaven, Germany, 26389
- Klinikum Wilhelmshaven
-
Würselen, Germany, 52146
- Hämatologisch-Onkologische Praxis
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
Metastatic and inoperable, colorectal cancer who has progressed on/after, or did not tolerate, refuse or have contraindications to: fluoropyrimidines, oxaliplatin, irinotecan, anti-angiogenic therapies (bevacizumab, aflibercept, regorafenib or ramucirumab) and if indicated anti-EGFR antibodies (cetuximab or panitumumab).
Intolerance is defined as a permanent discontinuation of the respective treatment resulting from toxicity
- Signed informed consent before start of specific protocol procedure
- Histologically or cytologically documented diagnosis of adenocarcinoma of the colon or rectum
- Presence of at least one measurable site of disease following RECIST 1.1 criteria
- ECOG (Eastern Cooperative Oncology Group) performance 0-1
- Known RAS and BRAF V600E mutational status
- Life expectancy of at least 3 months
Adequate hematological, hepatic and renal function parameters:
- Leukocytes ≥3000/mm³, platelets ≥100,000/mm³, neutrophil count (ANC) ≥1500/μL, hemoglobin ≥9 g/dL (5.58 mmol/L)
- Adequate coagulation function as defined by International Normalized Ratio (INR) ≤1.5, and a partial thromboplastin time (PTT) ≤5 seconds above the ULN (upper limit of normal) (unless receiving anticoagulation therapy). Patients receiving warfarin/phenprocoumon must be switched to low molecular weight heparin and have achieved a stable coagulation profile prior to first dose of protocol therapy
- Serum creatinine ≤1.5 x upper limit of normal or creatinine clearance (measured via 24-hour urine collection) ≥40 mL/minute (that is, if serum creatinine is >1.5 times the ULN, a 24-hour urine collection to calculate creatinine clearance must be performed)
- Urinary protein ≤1+ on dipstick or routine urinalysis (UA; if urine dipstick or routine analysis is ≥2+, a 24-hour urine collection for protein must demonstrate <1000 mg of protein in 24 hours to allow participation in this protocol)
- Bilirubin ≤1.5 x upper limit of normal, AST and ALT ≤3.0 x upper limit of normal, ≤5xULN if liver metastasis present, alkaline phosphatase ≤6 x upper limit of normal
- Patient able and willing to provide written informed consent and to comply with the study protocol
- Female and male patients ≥18. Patients in reproductive age must be willing to use adequate contraception during the study and for 7 months after the end of ramucirumab treatment (appropriate contraception is defined as surgical sterilization (e.g., bilateral tubal ligation, vasectomy) or hormonal contraception (implantable, patch, oral). Women who use a hormonal contraception method should use an additional barrier method like IUD, male or female condom with spermicidal gel, diaphragm, sponge, cervical cap). Female patients with childbearing potential need to have a negative pregnancy test within 7 days before study start (There are no data that indicate special gender distribution. Therefore, patients will be enrolled in the study gender-independently.)
Exclusion Criteria:
- Known hypersensitivity against ramucirumab or TAS102
- Other known contraindications against ramucirumab, TAS102, or other anti-angiogenic therapies
- Prior therapy with TAS102
- Drug-related severe adverse events upon pretreatment with antiangiogenic drugs that would require permanent discontinuation and not allow re-challenge with the same class of drug (i.e. ramucirumab) such as noncontrollable severe hypertension or thromboembolic events
- Any antineoplastic treatment including irradiation within 14 days (42 days for mitomycin c) prior to start of therapy.
- Major surgery within 4 weeks of starting therapy within this study, or minor surgery/subcutaneous venous access device placement within 7 days prior to first dose of protocol therapy. The patient has elective or planned major surgery to be performed during the course of the clinical trial.
- Symptomatic brain metastasis
Clinically significant cardiovascular disease
- NYHA>II°, myocardial infarction within 6 months prior study entry
- Known clinically significant valvular defect
- Uncontrolled or poorly-controlled hypertension (>160 mmHg systolic or >100 mmHg diastolic for >4 weeks) despite standard medical management
- Any arterial thromboembolic events, including but not limited to myocardial infarction, transient ischemic attack, cerebrovascular accident, or unstable angina, within 6 months prior to first dose of protocol therapy
- History of deep vein thrombosis (DVT), symptomatic pulmonary embolism (PE), or any other significant thromboembolism (venous port or catheter thrombosis or superficial venous thrombosis are not considered "significant") during the 3 months prior to first dose of protocol therapy
- Active clinically serious infections (> grade 2 NCI-CTC version 4.0)
- Chronic inflammatory bowel disease
- History of uncontrolled HIV infection or chronic hepatitis B or C
- Patients with evidence of bleeding diathesis
- Grade 3-4 GI bleeding within 3 months prior to first dose of protocol therapy
- Receiving chronic antiplatelet therapy, including aspirin (once daily aspirin use (maximum dose 325 mg/day) is permitted), nonsteroidal anti-inflammatory drugs (including ibuprofen, naproxen, and others), dipyridamole or clopidogrel, or similar agents
- History of gastrointestinal perforation or fistulae in past 6 months or risk factors for perforation
- Serious or nonhealing wound, ulcer, or bone fracture within 28 days prior to first dose of protocol therapy
- Past or current history of other malignancies not curatively treated and without evidence of disease for more than 5 years, except for curatively treated basal cell carcinoma of the skin and in situ carcinoma of the cervix or bladder, or low/intermediate risk prostate cancer (Gleason score ≤7) with normal PSA levels
- Any condition that could jeopardize the safety of the patient and their compliance of the study
- Medical, psychological or social conditions that may interfere with the participation in the study
Cirrhosis at a level of Child-Pugh B (or worse) or cirrhosis (any degree) and a history of hepatic encephalopathy or ascites.
Clinically meaningful ascites is defined as ascites from cirrhosis requiring diuretics or paracentesis
- On-treatment participation in another clinical study or received investigational drug therapy in the period 30 days prior to inclusion and during the study
- Subject pregnant or breast feeding, or planning to become pregnant within 7 months after the end of treatment
- Patients in a closed institution according to an authority or court decision (AMG § 40, Abs. 1 No. 4)
- Any other concurrent antineoplastic treatment including irradiation
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Arm A (ramucirumab + TAS102)
Patients randomized to arm A will receive ramucirumab 8 mg/kg iv over 60 min on d1+15, q4w and TAS102 35mg/m2 p.o. twice daily (BID) d1-5 and 8-12, q4w until progression or intolerance or completion of 6 cycles.
|
8 mg/kg iv over 60 min on d1+15, q4w
35mg/m2 p.o. twice daily (BID) d1-5 and d8-12, q4w
|
Active Comparator: Arm B (TAS102 only)
Patients randomized to arm B will receive TAS102 35mg/m2 p.o. twice daily (BID) d1-5 and 8-12, q4w until progression, intolerance or completion of 6 cycles.
|
35mg/m2 p.o. twice daily (BID) d1-5 and d8-12, q4w
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Overall survival
Time Frame: Up to 4 years
|
Overall survival according to Kaplan-Meier
|
Up to 4 years
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Overall response rate (ORR)
Time Frame: Up to 4 years
|
ORR defined as the proportion of patients with complete or partial remission according to RECIST 1.1
|
Up to 4 years
|
Disease control rate (DCR)
Time Frame: Up to 4 years
|
DCR defined as the proportion of patients with complete or partial remission and stable disease according to RECIST 1.1
|
Up to 4 years
|
Progression-free survival (PFS)
Time Frame: Up to 4 years
|
PFS, defined as the time from enrollment/randomization to the first occurrence of progression, as determined by the investigator using CT criteria, or death from any cause
|
Up to 4 years
|
Overall survival (OS) rate at different time points
Time Frame: 6 months and 1 year
|
OS rate at 6 and 12 months, defined as patients who are alive after at 6 and 12 months, respectively
|
6 months and 1 year
|
Efficacy (ORR) subgroup
Time Frame: Up to 4 years
|
Efficacy (ORR) in patients who develop neutropenia grade ≥2 (ANC ≤1500/μl) in cycle 1
|
Up to 4 years
|
Efficacy (PFS) subgroup
Time Frame: Up to 4 years
|
Efficacy (PFS) in patients who develop neutropenia grade ≥2 (ANC ≤1500/μl) in cycle 1
|
Up to 4 years
|
Efficacy (OS) subgroup
Time Frame: Up to 4 years
|
Efficacy (OS) in patients who develop neutropenia grade ≥2 (ANC ≤1500/μl) in cycle 1
|
Up to 4 years
|
Quality of life I (QoL)
Time Frame: Up to 1 year
|
Quality of life (QoL) as measured by EORTC-QLQ-C30 at d1 of each cycle and on EOT (end of treatment).
|
Up to 1 year
|
Quality of life II (QoL)
Time Frame: Up to 1 year
|
Quality of life (QoL) as measured by EQ-5D-5L at d1 of each cycle and on EOT.
|
Up to 1 year
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Explorative: Overall response rate (ORR)
Time Frame: Up to 4 years
|
ORR according to gene expression, mutational profiles, plasma biomarkers and radiologic analysis
|
Up to 4 years
|
Explorative: Overall survival (OS)
Time Frame: Up to 4 years
|
OS according to gene expression, mutational profiles, plasma biomarkers and radiologic analysis
|
Up to 4 years
|
Explorative: Progression-free survival (PFS)
Time Frame: Up to 4 years
|
PFS according to gene expression, mutational profiles, plasma biomarkers and radiologic analysis
|
Up to 4 years
|
Collaborators and Investigators
Investigators
- Study Chair: Salah-Eddin Al-Batran, Prof. Dr., Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- RAMTAS
- 2017-004162-99 (EudraCT Number)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Colorectal Cancer
-
University of California, San FranciscoCompletedStage IV Colorectal Cancer AJCC v8 | Stage IVA Colorectal Cancer AJCC v8 | Stage IVB Colorectal Cancer AJCC v8 | Stage IVC Colorectal Cancer AJCC v8 | Stage III Colorectal Cancer AJCC v8 | Stage IIIA Colorectal Cancer AJCC v8 | Stage IIIB Colorectal Cancer AJCC v8 | Stage IIIC Colorectal Cancer AJCC... and other conditionsUnited States
-
Fred Hutchinson Cancer CenterNational Cancer Institute (NCI)TerminatedRectal Cancer | Colon Cancer | Cancer Survivor | Colorectal Adenocarcinoma | Stage III Colorectal Cancer AJCC v8 | Stage IIIA Colorectal Cancer AJCC v8 | Stage IIIB Colorectal Cancer AJCC v8 | Stage IIIC Colorectal Cancer AJCC v8 | Stage I Colorectal Cancer AJCC v8 | Stage II Colorectal Cancer AJCC v8 | Stage... and other conditionsUnited States
-
University of Southern CaliforniaNational Cancer Institute (NCI)TerminatedStage IV Colorectal Cancer AJCC v8 | Stage IVA Colorectal Cancer AJCC v8 | Stage IVB Colorectal Cancer AJCC v8 | Stage IVC Colorectal Cancer AJCC v8 | Stage III Colorectal Cancer AJCC v8 | Stage IIIA Colorectal Cancer AJCC v8 | Stage IIIB Colorectal Cancer AJCC v8 | Stage IIIC Colorectal Cancer AJCC... and other conditionsUnited States
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)Active, not recruitingStage IV Colorectal Cancer AJCC v8 | Stage IVA Colorectal Cancer AJCC v8 | Stage IVB Colorectal Cancer AJCC v8 | Stage IVC Colorectal Cancer AJCC v8 | Stage III Colorectal Cancer AJCC v8 | Stage IIIA Colorectal Cancer AJCC v8 | Stage IIIB Colorectal Cancer AJCC v8 | Stage IIIC Colorectal Cancer AJCC... and other conditionsUnited States
-
Wake Forest University Health SciencesNational Cancer Institute (NCI)CompletedCancer Survivor | Stage III Colorectal Cancer AJCC v8 | Stage IIIA Colorectal Cancer AJCC v8 | Stage IIIB Colorectal Cancer AJCC v8 | Stage IIIC Colorectal Cancer AJCC v8 | Stage I Colorectal Cancer AJCC v8 | Stage II Colorectal Cancer AJCC v8 | Stage IIA Colorectal Cancer AJCC v8 | Stage IIB Colorectal... and other conditionsUnited States
-
M.D. Anderson Cancer CenterRecruitingColorectal Adenocarcinoma | Stage IVA Colorectal Cancer AJCC v8 | Stage IVB Colorectal Cancer AJCC v8 | Stage IVC Colorectal Cancer AJCC v8 | Stage III Colorectal Cancer AJCC v8 | Stage IIIA Colorectal Cancer AJCC v8 | Stage IIIB Colorectal Cancer AJCC v8 | Stage IIIC Colorectal Cancer AJCC v8 | Stage... and other conditionsUnited States
-
City of Hope Medical CenterRecruitingColorectal Neoplasms | Colorectal Cancer | Colorectal Adenocarcinoma | Colorectal Cancer Stage II | Colorectal Cancer Stage III | Colorectal Cancer Stage IV | Colorectal Neoplasms Malignant | Colorectal Cancer Stage IUnited States, Japan, Italy, Spain
-
Sidney Kimmel Cancer Center at Thomas Jefferson...United States Department of DefenseActive, not recruitingColorectal Adenoma | Stage III Colorectal Cancer AJCC v8 | Stage IIIA Colorectal Cancer AJCC v8 | Stage IIIB Colorectal Cancer AJCC v8 | Stage IIIC Colorectal Cancer AJCC v8 | Stage 0 Colorectal Cancer AJCC v8 | Stage I Colorectal Cancer AJCC v8 | Stage II Colorectal Cancer AJCC v8 | Stage IIA Colorectal... and other conditionsUnited States
-
University of Roma La SapienzaCompletedColorectal Cancer Stage II | Colorectal Cancer Stage III | Colorectal Cancer Stage IV | Colorectal Cancer Stage 0 | Colorectal Cancer Stage IItaly
-
University of Southern CaliforniaNational Cancer Institute (NCI); AmgenTerminatedStage IV Colorectal Cancer AJCC v7 | Stage IVA Colorectal Cancer AJCC v7 | Stage IVB Colorectal Cancer AJCC v7 | Colorectal Adenocarcinoma | RAS Wild Type | Stage III Colorectal Cancer AJCC v7 | Stage IIIA Colorectal Cancer AJCC v7 | Stage IIIB Colorectal Cancer AJCC v7 | Stage IIIC Colorectal Cancer...United States
Clinical Trials on Ramucirumab
-
Shanghai Henlius BiotechTerminatedHealthy Male VolunteersChina
-
Yonsei UniversityNot yet recruiting
-
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.CompletedGastric Cancer | Non-small Cell Lung Cancer | Colo-rectal CancerChina
-
Eli Lilly and CompanyParexelCompleted
-
Eli Lilly and CompanyCompleted
-
Yale UniversityWithdrawnTransitional Cell CarcinomaUnited States
-
Eli Lilly and CompanyCompleted
-
Samsung Medical CenterRecruiting
-
Eli Lilly and CompanyCompletedHepatocellular CarcinomaUnited States, Canada, Belgium, Germany, Israel, Korea, Republic of, Spain, Australia, Austria, Brazil, France, Italy, Japan, Portugal, Taiwan, Romania, Bulgaria, Czech Republic, Finland, Hong Kong, Hungary, Netherlands, Norway, Phili... and more
-
Sidney Kimmel Comprehensive Cancer Center at Johns...National Cancer Institute (NCI); Eli Lilly and CompanyCompletedAdult Glioblastoma MultiformeUnited States